Racetams

The original "nootropic" family — piracetam (1960s, still prescribed in parts of Europe) and its descendants aniracetam, oxiracetam, and nefiracetam. Sunifiram (DM-235) is a related experimental compound derived from this research line, not structurally a racetam. Related entries: Noopept and phenylpiracetam have their own pages.

The racetams are a family built around piracetam, sharing a pyrrolidone ring and, beyond that, surprisingly little agreement about how they work. The most cited proposals are modulation of AMPA glutamate receptors, effects on acetylcholine signalling, and changes to cell membrane fluidity that alter how neurons handle signals. Which of these matters, or whether any does at the amounts people take, has never been resolved — and that uncertainty is the honest headline for the whole family rather than a footnote to it.

Piracetam has a genuinely large but old and mixed literature: signals in cognitive decline and post-stroke contexts, little convincing evidence in healthy adults. The descendants ride on smaller, mostly animal datasets — aniracetam's anxiolytic reputation, for instance, is primarily rodent work. Sunifiram has essentially no human record.

• Piracetam is the only member with a substantial human literature, and it is old, largely European, and concentrated in cognitive impairment and cortical myoclonus rather than in healthy people.
• A Cochrane review of piracetam for dementia and cognitive impairment concluded the evidence does not support its use, which is the most rigorous assessment the family has received.
• NONE SHOWN for cognitive enhancement in healthy adults, for any member. The trials either do not exist or do not demonstrate it.
• Aniracetam, oxiracetam, pramiracetam and phenylpiracetam have progressively less human evidence, mostly small, mostly Russian or Eastern European, and none independently replicated.
• FDA has taken enforcement action against products marketing piracetam as a dietary supplement, on the basis that it does not meet the dietary ingredient definition.

Piracetam is water-soluble, poorly protein-bound, and cleared renally largely unchanged. The others vary substantially — some are fat-soluble, some are claimed to be far more potent by weight, and none has adequately characterised human pharmacokinetics outside piracetam. Products are typically sold as bulk research-chemical powder of unverified identity.

Piracetam has a relatively extensive tolerability record; safety data become sparse for the newer members — nefiracetam's development was marked by animal toxicity findings, and sunifiram's potency-without-data profile puts it closer to the long-tail research compounds than to piracetam. No US product standard applies; purity is unverifiable.

• Anyone with kidney impairment, particularly for piracetam given renal clearance
• Anyone taking anticoagulants, given piracetam's antiplatelet activity
• Anyone pregnant or breastfeeding
• Anyone with an anxiety or sleep disorder, which the stimulating members commonly worsen
• Anyone consuming bulk research-chemical powder, where identity and contaminants are unverified

• Anticoagulants — piracetam has antiplatelet effects and has been studied for that property, so the interaction is more than theoretical.
• Other racetams, commonly stacked without any evidence that combinations do anything.
• Stimulants, where the more activating members compound sleep and anxiety effects.
• No adequately characterised interaction profile exists for most members.

• Headache is the most consistently reported effect across the family, and is commonly attributed to choline depletion, though that explanation is proposed rather than demonstrated.
• Irritability, anxiety and sleep disturbance, particularly with the stimulating members.
• Whether any perceived benefit persists past the first weeks, given how strong expectation effects are in this category.
• Kidney function is relevant for piracetam specifically, since it is renally cleared.

No withdrawal syndrome is described for any member. Reported effects fade over days. Since no controlled evidence establishes benefit in healthy people, there is no established effect to lose — which is also the honest answer to why so many people cycle through the family without settling on one.

US: not scheduled, not approved — the FDA has stated piracetam is not a legal dietary supplement ingredient. Prescription drug in parts of Europe.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Efficacy of piracetam in children with breath-holding spells: a systematic review and meta-analysis
  Eur J Pediatr, 2024
• Cognitive effects of piracetam in adults with memory impairment: A systematic review and meta-analysis
  Clin Neurol Neurosurg, 2024
• Piracetam in acute stroke: a systematic review
  J Neurol, 2000

• Nefiracetam facilitates hippocampal neurotransmission by a mechanism independent of the piracetam and aniracetam actionBrain Res · 2000
• [Levetiracetam]Neurologia · 2001
• A new antiepileptic drugJ Neurol Neurosurg Psychiatry · 2002
• Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trialSignal Transduct Target Ther · 2025
• Levetiracetam-induced thrombocytopeniaEpilepsia · 2004
• [Oxiracetam]G Clin Med · 1989
• Prolongation of latencies for passive avoidance responses in rats treated with aniracetam or piracetamPharmacol Biochem Behav · 1985
• Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysisFront Pharmacol · 2024
• Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disordersDrugs · 2010
• Oxiracetam alleviates anti-inflammatory activity and ameliorates cognitive impairment in the early phase of traumatic brain injuryActa Neurochir (Wien) · 2023
• Levetiracetam: treatment in epilepsyExpert Opin Pharmacother · 2003
• Piracetam and other structurally related nootropicsBrain Res Brain Res Rev · 1994